Cargando…

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches

Multiple sclerosis (MS) is characterized by chronic inflammation in conjunction with neurodegeneration within the central nervous system. Most individuals with MS begin with a relapsing remitting course that later transitions to secondary progressive MS. Currently available disease-modifying therapi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grand′Maison, Francois, Yeung, Michael, Morrow, Sarah A., Lee, Liesly, Emond, Francois, Ward, Brian J., Laneuville, Pierre, Schecter, Robyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183038/ https://www.ncbi.nlm.nih.gov/pubmed/30233054 http://dx.doi.org/10.4103/1673-5374.239432

Ejemplares similares

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies
por: Duquette, Pierre, et al.
Publicado: (2019)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β-1a
por: Vickrey, Barbara G., et al.
Publicado: (2015)

Neurofibromatosis I and multiple sclerosis
por: Bergqvist, Christina, et al.
Publicado: (2020)

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
por: Visser, Leo H, et al.
Publicado: (2016)

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
por: Sharmin, Sifat, et al.
Publicado: (2023)

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
por: Trojano, Maria, et al.
Publicado: (2012)

Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis
por: Lorefice, Lorena, et al.
Publicado: (2023)

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
por: Pardo, Gabriel, et al.
Publicado: (2017)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Erratum: Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis
por: Frontiers Production Office,
Publicado: (2023)

Cortical morphology predicts placebo response in multiple sclerosis
por: Cherkasova, Mariya V., et al.
Publicado: (2022)

Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies
por: Owens, Gary M., et al.
Publicado: (2013)

Multiple Sclerosis: Overview of Disease-Modifying Agents
por: Finkelsztejn, Alessandro
Publicado: (2014)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022)

Proteomics in Multiple Sclerosis: The Perspective of the Clinician
por: Sandi, Dániel, et al.
Publicado: (2022)

Time perspective of patients with multiple sclerosis
por: Dogru Huzmeli, Esra, et al.
Publicado: (2023)

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
por: Longbrake, Erin E, et al.
Publicado: (2016)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

The role of exercise in modifying outcomes for people with multiple sclerosis: a randomized trial
por: Mayo, Nancy E, et al.
Publicado: (2013)

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
por: Martínez-López, Iciar, et al.
Publicado: (2020)

The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
por: Shahtaheri, Rahil Sadat, et al.
Publicado: (2020)

Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications
por: Levit, Elle, et al.
Publicado: (2022)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kjdemv1ksroeupdtbf0lpgm5k9